Form 4: Apellis Pharmaceuticals Grants Equity Awards to Chief People Officer Kelley Boucher

Apellis Pharmaceuticals, Inc. has reported the grant of restricted stock units and stock options to its Chief People Officer, Kelley Boucher, as part of standard executive compensation.

Summary

• Kelley Boucher, Chief People Officer of Apellis Pharmaceuticals, Inc. (APLS), was granted 22,087 shares of Common Stock in the form of restricted stock units (RSUs) on May 28, 2025.
• These RSUs will fully vest on the first anniversary of the grant date, subject to her continued service as an officer.
• Additionally, Ms. Boucher was granted 32,976 stock options with an exercise price of $16.8 per share on May 28, 2025.
• The stock options vest over a four-year period, with 25% vesting one year from the grant date and the remaining 75% vesting monthly thereafter, also subject to continued service.

Sentiment

Score: 7

Explanation: The document reports a standard and positive event of executive compensation through equity grants, which aligns management's interests with shareholders and aids in retention. There are no negative implications or risks disclosed within this specific filing.

Positives

• The equity grants align the Chief People Officer's interests with those of shareholders, incentivizing long-term performance and value creation.
• The vesting schedules for both RSUs and stock options are designed to promote executive retention and continued service to the company.

Future Outlook

The equity grants are structured with vesting schedules that extend into the future, indicating an expectation of continued service from the Chief People Officer and a long-term alignment of interests.

Management Comments

• The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to her continued service as an officer, or upon later termination of her service.
• This represents a stock option award granted May 28, 2025 that vests over a four-year period. 25% vests one year from grant date and the remaining 75% vests monthly thereafter subject to continued service.

Industry Context

The granting of restricted stock units and stock options to key executives is a common practice in the biotechnology and pharmaceutical industries, serving as a standard component of executive compensation packages designed to attract, retain, and incentivize top talent.

Comparison to Industry Standards

• This filing details a specific executive's compensation, and without broader context on Apellis's overall compensation philosophy or a peer group analysis, a direct comparison to industry standards for executive compensation packages is not feasible from this document alone.
• The use of RSUs and stock options with multi-year vesting schedules is consistent with typical executive incentive structures across the biotech sector, aiming to align executive performance with long-term shareholder value.

Stakeholder Impact

• Shareholders: The equity grants are intended to align the interests of the Chief People Officer with those of shareholders, potentially leading to improved long-term performance and value creation.
• Employees: While specific to one executive, such compensation practices can signal a commitment to competitive remuneration, potentially influencing overall employee morale and retention strategies.

Next Steps

• Kelley Boucher's continued service to Apellis Pharmaceuticals, Inc. to fulfill the vesting conditions of the granted RSUs and stock options.

Key Dates

Keywords

Apellis Pharmaceuticals, APLS, Form 4, Equity Grant, Restricted Stock Units, Stock Options, Executive Compensation, Insider Transaction, Kelley Boucher